Analysed patients (n = 103) | Responders (n = 70) | Non-responders (n = 33) | p Value | |
Demographics: | ||||
Age (years) | 55 (13) | 54 (13) | 56 (12) | 0.40 |
Female (%) | 71 (69) | 51 (73) | 20 (61) | 0.21 |
Disease status: | ||||
Disease duration (months) | 125 (110) | 123 (111) | 130 (110) | 0.80 |
Erosive disease (%) | 79 (77) | 57 (81) | 22 (67) | 0.10 |
RF positive (%) | 77 (75) | 57 (81) | 20 (61) | 0.02 |
Anti-CCP positive (%) | 78 (76) | 57 (81) | 13 (39) | 0.08 |
DAS28 | 5.9 (1.1) | 6.0 (1.0) | 5.6 (1.2) | 0.07 |
Patients global score (0–100 mm) | 60 (22) | 62 (21) | 56 (23) | 0.23 |
ESR (mm/h) | 34 (24) | 36 (23) | 29 (25) | 0.16 |
CRP (mg/dl) | 22 (28) | 24 (26) | 19 (30) | 0.36 |
Drug treatments: | ||||
Previous DMARDs | 2.2 (1.5) | 2.1 (1.4) | 2.4 (1.6) | 0.42 |
Methotrexate (mg/week) | 18.8 (8.5) | 19.5 (8.2) | 17.1 (8.9) | 0.18 |
Receiving corticosteroids (%) | 28 (27) | 22 (31) | 6 (18) | 0.22 |
Receiving NSAIDs (%) | 52 (50) | 35 (50) | 17 (52) | 0.89 |
Mean (SD), median and interquartile range (IQR) or percentages are shown. p Values <0.05 (two-sided) were considered significant.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor.